Cardio-oncology
is the discipline that concentrates on the intersection of heart diseases and cancer. This field is growing at a faster rate because the
survivors after cancer therapies are more prone to develop
cardiovascular disease. The increase in cancer disease in the world has
led to the emergence of numerous chemotherapeutic agents which are under
pre-clinical or clinical studies. These agents are potent to cause
damage to the heart (cardiotoxicity). Cardiotoxic effects of
chemotherapy might be decreased by the concurrent use of
angiotensin-converting enzyme inhibitors, angiotensin receptor blockers
or beta-blockers. The use of diagnostic imaging, noninvasive stress
testing, serum biomarkers, ambulatory blood pressure monitoring and ambulatory cardiac telemetry can help to identify cardiotoxicities and lead to the development of preventative strategies.
Cardiotoxic therapy
Cardiotoxicity
Cardiac tumors
Cancer and blood clots
Cancer and blood vessels
Cancer and heart failure
Cardiac biomarkers
Cardiotoxicity
Cardiac tumors
Cancer and blood clots
Cancer and blood vessels
Cancer and heart failure
Cardiac biomarkers
 |
| Track 6: Cardio-Oncology |
Vanesa Gregorietti, Chairman and President Cardiology Society of Buenos Aires Argentina will be the chief guest who will deliver a keynote speech.
Interested in presenting can submit their abstarct for Speaker Presentation through the link: https://cardiologysummit.cardiologymeeting.com/abstract-submission.php
Register for this Congress at : https://cardiologysummit.cardiologymeeting.com/registration.php
We welcome your queries. E-mail us at cardiology@expertscongress.com
No comments:
Post a Comment
Note: only a member of this blog may post a comment.